Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: sertraline hydrochloride

« Back to Dashboard

Sertraline hydrochloride is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Ranbaxy Labs Ltd, Roxane, Pfizer, Accord Hlthcare, Actavis Elizabeth, Apotex Inc, Austarpharma Llc, Cipla Ltd, Dr Reddys Labs Ltd, Hikma Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mutual Pharm, Mylan, Mylan Pharms Inc, Pliva Hrvatska Doo, Prosam Labs, Ranbaxy, Sandoz, Sun Pharm Inds (in), Teva, Torrent Pharms, Watson Labs, Wockhardt, and Zydus Pharms Usa, and is included in thirty-one NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for sertraline hydrochloride. Thirteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: sertraline hydrochloride

Tradenames:2
Patents:2
Applicants:27
NDAs:31
Drug Master File Entries: see list22
Suppliers: see list13
Therapeutic Class:Antidepressants
Anxiolytics

Pharmacology for Ingredient: sertraline hydrochloride

Tentative approvals for SERTRALINE HYDROCHLORIDE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL200MG
<disabled><disabled>TABLET; ORAL150MG

Clinical Trials for: sertraline hydrochloride

An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia
Status: Completed Condition: Depression

Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects
Status: Completed Condition: Healthy

Special Investigation Of Long Term Use Of Sertraline.
Status: Completed Condition: Depression; Panic Disorder

Pharmacokinetic Properties of Sertraline Before and After Gastric Bypass Surgery
Status: Active, not recruiting Condition: Roux en Y Gastric Bypass Surgery

Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mutual Pharm
SERTRALINE HYDROCHLORIDE
sertraline hydrochloride
TABLET;ORAL077818Feb 6, 2007DISCNNo<disabled><disabled>
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839Dec 30, 1991RXNo<disabled><disabled>
Austarpharma Llc
SERTRALINE HYDROCHLORIDE
sertraline hydrochloride
TABLET;ORAL078677Mar 4, 2009RXNo<disabled><disabled>
Pfizer
ZOLOFT
sertraline hydrochloride
CONCENTRATE;ORAL020990Dec 7, 1999RXYes6,727,283*PED<disabled>Y<disabled>
Prosam Labs
SERTRALINE HYDROCHLORIDE
sertraline hydrochloride
TABLET;ORAL078175Jul 21, 2010RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc